The current article highlights the role of the mitochondrial melatonergic pathway in GBM/GSC pathophysiology and tumour microenvironment interactions, including via the regulation of the circadian genes CLOCK and Bmal1, which modulate temozolomide efficacy[5]. The gene discussed is CLOCK; the disease is glioblastoma.